There has been a new step forward in the development of an effective vaccine against H5N1, the bird flu virus that's also dangerous to humans. By adding an agent that stimulates the immune system, it appears that the existing vaccine is effective against various strains of the bird flu virus.
Uncertainty has been the biggest problem in developing an effective vaccine against the variant of H5N1 that's dangerous to humans. Uncertainty about which strain of the virus it is, and uncertainty over which type of bird flu could develop into a flu virus that might cause a worldwide epidemic. That made it almost impossible to develop a preventative vaccine. But with the discovery made by the British pharmaceutical company Glaxo Smith Klein, uncertainty over the virus strain has become less significant.
Breakthrough
The improved vaccine has been tested by Viro-Clinics, part of the Erasmus Medical Centre in Rotterdam. According to virologist Ab Osterhaus, there are several reasons to speak of a breakthrough:
"The vaccine protects against different variants of the H5N1 virus, including new strains."
According to the virologist, that's unique.
"We have always had to react after the event, but now we can produce a vaccine that offers protection against new and forthcoming variants of the same virus."
What's more, tests have shown that by adding the agent, a lot less vaccine is required. And that's very important during a worldwide flu epidemic, when huge quantities of vaccine are needed.
Response
The agent is a so-called adjuvant that is added to a medicine to strengthen its effectiveness. In this case, the substance stimulates the immune system and improves the response to the vaccine. The Erasmus Medical Centre tested the agent on people and on ferrets which, like people, suffer from flu viruses. Osterhaus explained the results:
"The humans appeared to have a relatively broad immune response. The ferrets were first vaccinated, then exposed to H5N1, and there too we witnessed a demonstrably broad protection against the virus."
Pandemic
H5N1 is generally regarded as the bird flu virus that can develop into a pandemic virus. It first appeared in Asia in 1996, and then spread very quickly across the whole world. In Africa, Europe and the Middle East the virus was subsequently identified. Millions of poultry were killed, and more than a hundred people died as a result of the flu virus.
H5N1 is one of the high-pathogenic viruses: 90 percent of people who are affected eventually die. Up to now, the virus has not mutated into a variant that can be passed from one human to another.
The World Health Organisation (WHO) regards the virus as the major potential cause of a pandemic, but there are other types. Spanish flu, which killed 50 million people worldwide in 1918, was of the type H1N1.
Supplies
Osterhaus is pleading for the supply of large quantities of the vaccine and adjuvant against H5N1. As soon as the flu virus develops into a variant which can be passed on from person to person, and a pandemic is lurking, the adjuvant can be added to the vaccine. In addition, supplies of antiviral agents such as Tamiflu must remain at the same level.
Although it is not certain that H5N1 will develop into a pandemic virus, virologist Ab Osterhaus pleads for vigilance:
"The danger to humans will always remain. With this discovery it's possible to prevent many infections at an early stage. But if the virus is of a different subtype, the production of a new vaccine will take at least several months."
* RNW translation (as)
Tags: Bird flu, Erasmus Medical Centre, Glaxo Smith Klein, H5N1, pandemic, Rotterdam, vaccine
Related articles:
- Dutch braced for bird flu
- FAO wants global anti-bird flu brigade
- Dutch prepare anti-bird flu vaccination plan
- H5N1-variant bird flu reaches western Europe
- Africa tackling major threat from bird flu
- Turkish family devastated by bird flu outbreak
- Bird flu – answers to some frequently asked questions
- Get ready now: why we have to act fast against bird flu
- The threat of bird flu - Dutch approach contrasts with the rest of Europe
- Thai bird flu blunders
